Gene Expression Profiling of Infant Embryonal Central Nervous System Tumors by Microarray Gene Chip Analysis: Angiogenesis, Invasion and Metastasis
N/A
2 Years
Both
Central Nervous System Embryonal Neoplasm
Trial Information
Gene Expression Profiling of Infant Embryonal Central Nervous System Tumors by Microarray Gene Chip Analysis: Angiogenesis, Invasion and Metastasis
OBJECTIVES:
- Identify known genes that have significantly different levels of expression, using
microarray gene chip analysis, in infants with newly diagnosed metastatic vs
non-metastatic embryonal central nervous system tumors.
- Determine the protein expression of genes identified by microarray analysis that are
involved in cellular functions that regulate angiogenesis, invasion, or metastasis in
this patient population.
- Determine the quantity of gene expression of the confirmed translationally expressed
genes using semi-quantitative polymerase chain reaction.
OUTLINE: This is a multicenter study.
Tumor samples are analyzed using microarray gene chip analysis. Differentially expressed
genes are evaluated for protein expression by standard immunohistochemistry and/or Western
blot analysis, and gene expression is further quantified by semi-quantitative polymerase
chain reaction.
PROJECTED ACCRUAL: Approximately 80-100 patients (20-25 with metastatic disease and 60-75
with non-metastatic disease) will be accrued for this study within 4-5 years.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Histologically confirmed, newly diagnosed, primary intracranial embryonal central
nervous system tumor
- Medulloblastoma
- Primitive neuroectodermal tumor
- Medulloepithelioma
- Ependymoblastoma
- Neuroblastoma
- Pineoblastoma
- Atypical teratoid/rhabdoid tumor
- Intracranial germ cell tumor
- Choroid plexus carcinoma
- M positive ependymoma
- Potential enrollment on PBTC-001 therapeutic protocol
PATIENT CHARACTERISTICS:
Age:
- Under 3
Performance status:
- Not specified
Life expectancy:
- Not specified
Hematopoietic:
- Not specified
Hepatic:
- Not specified
Renal:
- Not specified
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- No prior chemotherapy
Endocrine therapy:
- Prior steroids allowed
Radiotherapy:
- No prior radiotherapy
Surgery:
- Not specified
Other:
- No concurrent investigational agents
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Genes that are expressed in metastatic vs. non-metastatic tumors
Outcome Time Frame:
Prior to therapy
Safety Issue:
No
Principal Investigator
Tobey MacDonald, MD
Investigator Role:
Study Chair
Investigator Affiliation:
Children's Research Institute
Authority:
United States: Federal Government
Study ID:
CDR0000068446
NCT ID:
NCT00010114
Start Date:
March 2001
Completion Date:
March 2003
Related Keywords:
- Central Nervous System Embryonal Neoplasm
- childhood central nervous system germ cell tumor
- childhood choroid plexus tumor
- untreated childhood supratentorial primitive neuroectodermal tumor
- untreated childhood medulloblastoma
- newly diagnosed childhood ependymoma
- Neoplasms
- Neoplasms, Germ Cell and Embryonal
- Nervous System Neoplasms
- Central Nervous System Neoplasms
Name | Location |
|---|---|
| Baylor College of Medicine | Houston, Texas 77030 |
| Children's Hospital of Philadelphia | Philadelphia, Pennsylvania 19104 |
| Duke Comprehensive Cancer Center | Durham, North Carolina 27710 |
| UCSF Cancer Center and Cancer Research Institute | San Francisco, California 94115-0128 |
| Dana-Farber Cancer Institute | Boston, Massachusetts 02115 |
| Children's National Medical Center | Washington, District of Columbia 20010-2970 |
| Children's Hospital of Pittsburgh | Pittsburgh, Pennsylvania 15213 |
| Children's Hospital and Regional Medical Center - Seattle | Seattle, Washington 98105 |
| Saint Jude Children's Research Hospital | Memphis, Tennessee 38105-2794 |
